HTG Molecular Diagnostics, Inc. (HTGM) Rating Lowered to Strong Sell at ValuEngine
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
Several other research analysts have also commented on HTGM. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of HTG Molecular Diagnostics in a report on Thursday, June 29th. Zacks Investment Research lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Canaccord Genuity lifted their price objective on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the company a “hold” rating in a research note on Wednesday, April 19th. Finally, Rodman & Renshaw lifted their price objective on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, May 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. HTG Molecular Diagnostics currently has an average rating of “Hold” and a consensus target price of $5.75.
Shares of HTG Molecular Diagnostics (HTGM) traded down 4.96% during midday trading on Thursday, reaching $2.30. 284,749 shares of the company traded hands. The stock’s market capitalization is $21.91 million. The company’s 50 day moving average is $3.37 and its 200-day moving average is $3.31. HTG Molecular Diagnostics has a 12 month low of $1.20 and a 12 month high of $13.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Monday, May 15th. The medical research company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.15. HTG Molecular Diagnostics had a negative net margin of 440.31% and a negative return on equity of 1,538.49%. The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $2.44 million. Equities research analysts forecast that HTG Molecular Diagnostics will post ($2.25) earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA purchased a new stake in HTG Molecular Diagnostics during the first quarter worth about $228,000. Two Sigma Securities LLC bought a new stake in HTG Molecular Diagnostics during the first quarter worth $150,000. UBS Group AG bought a new stake in HTG Molecular Diagnostics during the first quarter worth $137,000. Finally, Renaissance Technologies LLC increased its stake in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares during the last quarter. Institutional investors own 31.30% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.